Novavax has finally concluded their submission seeking provisional approval of their COVID-19 vaccine. The Novavax vaccine is a more ‘traditional’ protein sub-unit vaccine that could help increase vaccination rates amongst those sceptical of the mRNA and viral vector vaccine technology. So far, phase 3 clinical trials have shown promising results – an efficacy of 90.4% against illness and 100% protection against severe illness amongst 30,000 participants.
A raft of restrictions are being eased weeks ahead of schedule in NSW thanks to continued low case numbers and soaring vaccination rates. From November 8, there will be no limit on home visitors, no rules for outdoor gatherings less than 1000, business capacity limits will double, nightclubs will reopen dance floors, and caps will be removed for all settings except gyms and dance classes. However, these freedoms will only be enjoyed by fully vaccinated people in the state.
Australia has now formally recognised two more vaccines – the BBIBP-CorV vaccine from China and the Covaxin vaccine from India. This has opened up the way for people vaccinated with either to establish their vaccination status when travelling to Australia. Both vaccines provide protection against COVID-19, and potentially reduce the likelihood of people transmitting the virus to others.
All people should use CPAP - here’s why
Israel – the first to vaccinate, first to reopen, first to offer booster shots. Now, just 6 weeks after a dangerous COVID-19 wave due to the Delta variant, Israel is returning to life close to normal. Deaths and infections have plummeted – largely thanks to booster shots and vaccine passports.
Research shows that living an active lifestyle can lower the risk of developing obstructive sleep apnea (OSA) - a common sleep disorder where the upper airways collapse during sleep resulting in airflow blockage.
A new study published in Lancet Global Health has shown that a cheap antidepressant, called fluvoxamine, could be used to treat COVID-19. The drug is known to reduce inflammation, and a new study has shown it can reduce the risk of hospitalisation and mortality in COVID-19 patients. In the latest trial, fluvoxamine was shown to reduce the relative risk of hospitalisation or extended emergency care by 32% and the mortality risk by more than 90%.
A third dose of the Pfizer vaccine has been provisionally approved for Australians as a booster 6 months after their first 2 COVID-19 shots. The booster can be used regardless of whether the person had Pfizer for their first 2 doses. Health Minister Greg Hunt is hopeful that the booster program will be launched on November 8. By January, 1.6 million will be due for their booster.
